Navigation Links
OXiGENE Abstracts Published in ASCO Program

eve synergistic antitumor activity when administered concurrently. In animal studies, ZYBRESTAT has been shown to enhance the anti-tumor effects of several chemotherapeutic agents, several anti-angiogenic drugs, and radiation.

OXi4503 is a novel, second-generation vascular disrupting agent with potential intrinsic cytotoxicity exerted through an ortho-quinone metabolite. The drug candidate has demonstrated single-agent activity in human tumor xenograft models. Preclinical research with OXi4503 suggests that it not only shuts down tumor blood flow, but can also be metabolized into a compound which could assist with killing the remaining tumor cells at the periphery of the tumor by direct cytotoxic activity against tumor cells. In December 2004, the United Kingdom regulatory authorities accepted an application from our collaborators, Cancer Research UK, to initiate a dose-escalating Phase I clinical trial of OXi4503 in patients with advanced cancer. This trial is currently ongoing. In 2007, OXiGENE plans to initiate several preclinical studies to evaluate OXi4503 and possibly a Phase Ib clinical trial of OXi4503 in combination with an approved anti-angiogenic therapeutic.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release including the initiation of further clinical trials with
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting ... checkup and cleaning when he or she says you ... probably heard before, you may have several questions and ... be relieved to know it,s nothing to worry about. ... patients, questions and alleviate any anxiety the public may ...
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... 19, 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch ... pleased to provide this review of the Company,s recent ... "Over this past year, we achieved many ... extremely proud to say that Monarch America is in ... has ever been," stated Eric Hagen , CEO ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... Mass., Sept. 16, 2011 Hologic, Inc. (Hologic or ... developer, manufacturer and supplier of premium diagnostic products, medical ... healthcare needs of women, will focus on two new, ... International Papillomavirus Conference & Clinical Workshop (IPV) ...
... Siemens has appointed Kurt D. Bettenhausen Senior Vice ... research & development (R&D) division. Siemens Corporate Research ... emerging technologies, including new imaging processes that allow ... efficiency to reduce building energy consumption, and renewable ...
Cached Medicine Technology:Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 2Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 3Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 4Siemens Appoints New R&D Head for the U.S. 2
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 22, 2014 In recognition of Veteran’s ... to Hero Reward, a local organization that provides services ... , Located on a couple hundred acres in ... offers lodging, world class fishing, hunting, hiking, horseback riding, ... founded several years ago to support U.S. Service men ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Xarelto ... federal panel of judges has granted a request to ... the U.S. District Court, Eastern District of Louisiana. The ... order on December 12 to transfer over 50 Xarelto ... districts to the Louisiana court for consolidation under U.S. ...
(Date:12/22/2014)... Dallas, Texas (PRWEB) December 22, 2014 Luxury ... with Community Partners of Dallas to provide logistics ... A Dallas-based company, Peacock Alley has a long history of ... works. The additional sponsors of this year's Toy Drive were ... time to give back than the holidays. Providing gifts to ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... colonised by E. coli bacteria early in life have ... a study of infants carried out at the Sahlgrenska Academy at ... outnumber the cells in our bodies by a factor of ten ... maturation of the immune system. The normal bacterial flora in the ...
... 2012) Autism Speaks is pleased to announce the launch ... in Toddlers, or M-CHAT. The M-CHAT is a scientifically validated ... age to assess their risk for autism spectrum disorder (ASD). ... Fein, Ph.D. and clinical psychologist Marianne Barton, Ph.D. The American ...
... Scientists who found a way to make white fat behave ... new obesity treatments. Brown fat burns energy (preventing obesity), ... cells are associated with fat accumulation around organs in the ... an increased risk for diabetes and heart disease, the researchers ...
... participation in a brief training program designed to ... in how patients perceived their interactions with the ... empathy with patients usually drops during medical school ... of Massachusetts General Hospital (MGH) researchers will appear ...
... against serious pneumococcal disease does not offer full protection, ... of Gothenburg, Sweden, finding that the number of cases ... Each year an estimated 1 million children worldwide die ... those in poor countries, but pneumococcal bacteria cause disease ...
... 6, 2012) - Eye color may be an indicator of ... A study, led by the University of Colorado School of ... have vitiligo. It then follows, according to scientists, that people ... Vitiligo is an autoimmune skin disease in which pigment loss ...
Cached Medicine News:Health News:Gut flora affects maturation of B cells in infants 2Health News:Automated autism screening tool available on Autism Speaks website 2Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: